

# Andrea Biondi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/736771/publications.pdf>

Version: 2024-02-01

382  
papers

31,322  
citations

7568

77  
h-index

5679

162  
g-index

391  
all docs

391  
docs citations

391  
times ranked

34739  
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4642-4649.	1.6	2,425
2	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	12.6	1,983
3	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	12.6	1,749
4	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	27.0	1,548
5	Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. <i>Lancet, The</i> , 1998, 352, 1731-1738.	13.7	876
6	Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. <i>Lancet Oncology, The</i> , 2009, 10, 147-156.	10.7	850
7	Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 2938-2948.	1.6	747
8	Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. <i>Blood</i> , 2010, 115, 3206-3214.	1.4	685
9	A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. <i>Lancet, The</i> , 2007, 370, 240-250.	13.7	547
10	Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. <i>Blood</i> , 2011, 118, 2077-2084.	1.4	370
11	Biological and therapeutic aspects of infant leukemia. <i>Blood</i> , 2000, 96, 24-33.	1.4	358
12	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	11.9	357
13	Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. <i>Lancet, The</i> , 2002, 359, 1909-1915.	13.7	338
14	Cross-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program. <i>Journal of Immunology</i> , 2003, 171, 4552-4560.	0.8	334
15	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. <i>Lancet, The</i> , 2008, 372, 1484-1492.	13.7	318
16	Somatically acquired <i>JAK1</i> mutations in adult acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2008, 205, 751-758.	8.5	318
17	RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2014, 46, 116-125.	21.4	313
18	Gain-of-function mutations in <i>interleukin-7 receptor-1<math>\alpha</math></i> ( <i>IL7R<math>\alpha</math></i> ) in childhood acute lymphoblastic leukemias. <i>Journal of Experimental Medicine</i> , 2011, 208, 901-908.	8.5	307

#	ARTICLE	IF	CITATIONS
19	Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. <i>Lancet Oncology</i> , The, 2012, 13, 936-945.	10.7	282
20	Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis. <i>Blood Cells, Molecules, and Diseases</i> , 1997, 23, 380-394.	1.4	273
21	Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. <i>Blood</i> , 2003, 102, 981-986.	1.4	270
22	An immune-based biomarker signature is associated with mortality in COVID-19 patients. <i>JCI Insight</i> , 2021, 6, .	5.0	269
23	X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. <i>Science Immunology</i> , 2021, 6, .	11.9	267
24	Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RAR1± Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter "AIDA" Trial. <i>Blood</i> , 1998, 92, 784-789.	1.4	266
25	Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. <i>Blood</i> , 2004, 104, 307-313.	1.4	265
26	Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow. <i>Journal of Clinical Oncology</i> , 2009, 27, 5168-5174.	1.6	247
27	Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. <i>Blood</i> , 2006, 107, 4514-4523.	1.4	238
28	Molecular Analysis of the Progression from <i>Helicobacter pylori</i> "Associated Chronic Gastritis to Mucosa-Associated Lymphoid-Tissue Lymphoma of the Stomach. <i>New England Journal of Medicine</i> , 1998, 338, 804-810.	27.0	230
29	Therapy of Molecular Relapse in Acute Promyelocytic Leukemia. <i>Blood</i> , 1999, 94, 2225-2229.	1.4	217
30	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 683-697.	16.8	213
31	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. <i>Blood</i> , 2016, 127, 2101-2112.	1.4	208
32	Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. <i>Lancet</i> , The, 2001, 358, 1239-1241.	13.7	199
33	GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. <i>Blood</i> , 2005, 106, 447-453.	1.4	196
34	<i>IKZF1</i> <sup>plus</sup> Defines a New Minimal Residual Disease "Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1240-1249.	1.6	194
35	Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia. <i>Blood</i> , 1999, 94, 12-22.	1.4	193
36	Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. <i>Blood</i> , 2014, 123, 70-77.	1.4	189

#	ARTICLE	IF	CITATIONS
37	Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel $\text{CD}123$ -specific chimeric antigen receptor. <i>British Journal of Haematology</i> , 2013, 161, 389-401.	2.5	186
38	Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2246-2256.	1.6	186
39	Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. <i>British Journal of Haematology</i> , 1998, 102, 1035-1041.	2.5	184
40	Combined expression of pT1± and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3788-3793.	7.1	184
41	Structural Analysis Identifies Imidazo[1,2- <i>b</i> ]pyridazines as PIM Kinase Inhibitors with <i>in vitro</i> Antileukemic Activity. <i>Cancer Research</i> , 2007, 67, 6916-6924.	0.9	183
42	Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 375-381.	2.0	181
43	Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. <i>Haematologica</i> , 2007, 92, 952-959.	3.5	165
44	Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1293-1301.	2.0	165
45	Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. <i>Blood</i> , 2013, 122, 170-178.	1.4	162
46	Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. <i>Blood</i> , 2005, 106, 1419-1422.	1.4	152
47	Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. <i>Blood</i> , 2010, 116, 2644-2650.	1.4	141
48	Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 188-196.e4.	2.9	139
49	Extracorporeal Photochemotherapy Is Accompanied by Increasing Levels of Circulating CD4+CD25+GITR+Foxp3+CD62L+ Functional Regulatory T-Cells in Patients With Graft-Versus-Host Disease. <i>Transplantation</i> , 2007, 84, 31-39.	1.0	136
50	Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. <i>Cytometry Part B - Clinical Cytometry</i> , 2008, 74B, 331-340.	1.5	132
51	Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. <i>Italian Journal of Pediatrics</i> , 2014, 40, 65.	2.6	129
52	IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. <i>Blood</i> , 2014, 123, 1691-1698.	1.4	129
53	Immunocytochemical Diagnosis of Acute Promyelocytic Leukemia (M3) With the Monoclonal Antibody PG-M3 (Anti-PML). <i>Blood</i> , 1997, 90, 4046-4053.	1.4	128
54	Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. <i>Journal of Experimental Medicine</i> , 2009, 206, 1957-1970.	8.5	128

#	ARTICLE	IF	CITATIONS
55	Genetic Modification of Human T Cells with CD20: A Strategy to Purify and Lyse Transduced Cells with Anti-CD20 Antibodies. <i>Human Gene Therapy</i> , 2000, 11, 611-620.	2.7	126
56	Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia. <i>Molecular Therapy</i> , 2017, 25, 1933-1945.	8.2	126
57	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. <i>Haematologica</i> , 2013, 98, 1702-1710.	3.5	121
58	Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. <i>Nature Medicine</i> , 2018, 24, 474-483.	30.7	112
59	Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 919-926.	1.6	111
60	Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. <i>Blood</i> , 2002, 99, 2541-2544.	1.4	110
61	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. <i>Blood</i> , 2010, 116, 3013-3022.	1.4	110
62	Interleukin-17-producing T-Helper Cells as New Potential Player Mediating Graft-Versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2009, 88, 1261-1272.	1.0	108
63	Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Münster study group. <i>British Journal of Haematology</i> , 2010, 151, 132-142.	2.5	108
64	Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. <i>Estote parati. Bone Marrow Transplantation</i> , 2020, 55, 1900-1905.	2.4	104
65	Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. <i>Haematologica</i> , 2010, 95, 2144-2152.	3.5	102
66	Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells. <i>Human Gene Therapy Methods</i> , 2012, 23, 376-386.	2.1	102
67	Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. <i>Journal of Clinical Investigation</i> , 2020, 130, 6021-6033.	8.2	102
68	Managing children with chronic myeloid leukaemia (<sc>CML</sc>). <i>British Journal of Haematology</i> , 2014, 167, 33-47.	2.5	100
69	New policies to address the global burden of childhood cancers. <i>Lancet Oncology</i> , The, 2013, 14, e125-e135.	10.7	96
70	<sc>AIEOP</sc>-<sc>BFM</sc> Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 82-93.	1.5	96
71	Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. <i>Haematologica</i> , 2012, 97, 1582-1593.	3.5	95
72	Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. <i>Lancet Haematology</i> , the, 2016, 3, e80-e86.	4.6	95

#	ARTICLE	IF	CITATIONS
73	Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28327.	1.5	93
74	Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84, 359-369.	1.5	92
75	Moral distress in nurses in oncology and haematology units. <i>Nursing Ethics</i> , 2012, 19, 183-195.	3.4	86
76	Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 5559-5564.	1.4	83
77	How I treat infant leukemia. <i>Blood</i> , 2019, 133, 205-214.	1.4	82
78	Children with cancer in the time of COVID-19: An 8-week report from the six pediatric oncology centers in Lombardia, Italy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28410.	1.5	82
79	Identification of preleukemic precursors of hyperdiploid acute lymphoblastic leukemia in cord blood. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 38-43.	2.8	78
80	Somatic <i>PTPN11</i> mutations in childhood acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2005, 129, 333-339.	2.5	78
81	Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. <i>Blood</i> , 2009, 114, 3764-3768.	1.4	78
82	Establishment of bone marrow and hematopoietic niches in vivo by reversion of chondrocyte differentiation of human bone marrow stromal cells. <i>Stem Cell Research</i> , 2014, 12, 659-672.	0.7	78
83	Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. <i>Lancet Haematology</i> , 2018, 5, e641-e652.	4.6	78
84	C-kit+ cardiac progenitors exhibit mesenchymal markers and preferential cardiovascular commitment. <i>Cardiovascular Research</i> , 2011, 89, 362-373.	3.8	77
85	Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL. <i>Oncogene</i> , 2001, 20, 2900-2907.	5.9	76
86	Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): A model for sustainable development in pediatric oncology. <i>Pediatric Blood and Cancer</i> , 2014, 61, 345-354.	1.5	76
87	Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?. <i>British Journal of Haematology</i> , 2014, 164, 396-408.	2.5	76
88	In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. <i>Blood</i> , 2011, 117, 4736-4745.	1.4	73
89	Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). <i>Journal of Clinical Oncology</i> , 2018, 36, 244-253.	1.6	71
90	Regulatory T Cells and Extracorporeal Photochemotherapy: Correlation With Clinical Response and Decreased Frequency of Proinflammatory T Cells. <i>Transplantation</i> , 2009, 87, 1422-1425.	1.0	70

#	ARTICLE	IF	CITATIONS
91	Long-Term Results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: Insight on the Prognostic Value of DNA Index in the Framework of Berlin-Frankfurt-Muenster-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 283-289.	1.6	69
92	Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. <i>Blood</i> , 2014, 123, 1470-1478.	1.4	69
93	Neutralizing type I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. <i>Immunology and Cell Biology</i> , 2021, 99, 917-921.	2.3	69
94	Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. <i>Haematologica</i> , 2018, 103, 107-115.	3.5	68
95	Extramedullary involvement in patients with acute promyelocytic leukemia. <i>Cancer</i> , 1998, 83, 1522-1528.	4.1	66
96	A wide role for NOTCH1 signaling in acute leukemia. <i>Cancer Letters</i> , 2005, 219, 113-120.	7.2	66
97	IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I: identification and characterization of 35 novel $\pm$ -L-iduronidase (IDUA) alleles. <i>Human Mutation</i> , 2011, 32, E2189-E2210.	2.5	66
98	Catch me if you can: how AML and its niche escape immunotherapy. <i>Leukemia</i> , 2022, 36, 13-22.	7.2	66
99	Delineation of multiple deleted regions in 7q in myeloid disorders. <i>Genes Chromosomes and Cancer</i> , 1999, 25, 384-392.	2.8	65
100	What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?. <i>Haematologica</i> , 2013, 98, 1226-1231.	3.5	65
101	Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. <i>Blood</i> , 2004, 103, 2358-2362.	1.4	64
102	Enzymatic replacement therapy for Hunter disease: Up to 9years experience with 17 patients. <i>Molecular Genetics and Metabolism Reports</i> , 2015, 3, 65-74.	1.1	63
103	Mesenchymal Stromal Cell-Derived PTX3 Promotes Wound Healing via Fibrin Remodeling. <i>Journal of Investigative Dermatology</i> , 2016, 136, 293-300.	0.7	63
104	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. <i>Frontiers in Immunology</i> , 2020, 11, 1689.	4.8	63
105	Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak. <i>Critical Care</i> , 2021, 25, 80.	5.8	63
106	Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 22-38.	2.8	62
107	Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4030-E4039.	7.1	62
108	Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. <i>European Journal of Cancer</i> , 2019, 110, 120-126.	2.8	61

#	ARTICLE	IF	CITATIONS
109	t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. <i>Genes Chromosomes and Cancer</i> , 2000, 29, 325-332.	2.8	60
110	Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. <i>Experimental Hematology</i> , 2006, 34, 1218-1228.	0.4	60
111	Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. <i>Blood</i> , 2012, 119, 227-237.	1.4	59
112	A Randomized Controlled Trial of Preoperative Intra-Aortic Balloon Pump in Coronary Patients With Poor Left Ventricular Function Undergoing Coronary Artery Bypass Surgery*. <i>Critical Care Medicine</i> , 2013, 41, 2476-2483.	0.9	57
113	The SIOPE strategic plan: A European cancer plan for children and adolescents. <i>Journal of Cancer Policy</i> , 2016, 8, 17-32.	1.4	57
114	A Human Immunodeficiency Virus Type 1 polGene-Derived Sequence (cPPT/CTS) Increases the Efficiency of Transduction of Human Nondividing Monocytes and T Lymphocytes by Lentiviral Vectors. <i>Human Gene Therapy</i> , 2002, 13, 1793-1807.	2.7	56
115	FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 89-92.	2.5	56
116	Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. <i>British Journal of Haematology</i> , 2015, 169, 711-718.	2.5	56
117	Microclustering of TEL-AML1 translocation breakpoints in childhood acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2000, 29, 219-228.	2.8	53
118	Characterization of Platelet Lysate Cultured Mesenchymal Stromal Cells and Their Potential Use in Tissue-Engineered Osteogenic Devices for the Treatment of Bone Defects. <i>Tissue Engineering - Part C: Methods</i> , 2010, 16, 201-214.	2.1	53
119	Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 1997, 90, 479-488.	1.4	52
120	Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B $\alpha$ cell precursor acute lymphoblastic leukemia cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2008, 74B, 150-155.	1.5	51
121	A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. <i>Haematologica</i> , 2009, 94, 781-789.	3.5	50
122	The silent mutational landscape of infant <i>MLL $\Delta$ AF4</i> pro $\alpha$ B acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 954-960.	2.8	50
123	Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. <i>Blood</i> , 2014, 124, 106-110.	1.4	50
124	Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB- $\eta$ activating signal. <i>Experimental Hematology</i> , 2007, 35, 1388-1397.	0.4	49
125	PAX5/TEL Acts as a Transcriptional Repressor Causing Down-modulation of CD19, Enhances Migration to CXCL12, and Confers Survival Advantage in pre-BI Cells. <i>Cancer Research</i> , 2008, 68, 181-189.	0.9	49
126	Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 295-299.	3.5	49



#	ARTICLE	IF	CITATIONS
127	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2070-2078.	2.0	48
128	Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM ALL-FLOW-MRD Study Group. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 147-153.	1.5	46
129	Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia. <i>Leukemia</i> , 2013, 27, 1204-1207.	7.2	45
130	A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The EndoSCORE. <i>International Journal of Cardiology</i> , 2017, 241, 97-102.	1.7	45
131	T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 1063-1075.	2.8	44
132	Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brain. <i>Neuropharmacology</i> , 2014, 79, 119-126.	4.1	44
133	Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform. <i>Oncotarget</i> , 2016, 7, 51581-51597.	1.8	43
134	Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. <i>British Journal of Haematology</i> , 1997, 97, 830-836.	2.5	41
135	Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. <i>Haematologica</i> , 2007, 92, 1407-1410.	3.5	41
136	Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. <i>Journal of Leukocyte Biology</i> , 2016, 99, 1077-1087.	3.3	41
137	Rituximab Unveils Hypogammaglobulinemia and Immunodeficiency in Children with Autoimmune Cytopenia. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 273-282.	3.8	41
138	Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. <i>Journal of Clinical Oncology</i> , 2021, 39, 652-662.	1.6	41
139	Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. <i>Haematologica</i> , 2017, 102, 1704-1708.	3.5	40
140	Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating Factor-Mobilized Circulating Progenitor Cells: Adequacy for Autologous and Allogeneic Transplantation. <i>Blood</i> , 1998, 91, 2189-2196.	1.4	40
141	Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL/AF4 positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1996, 92, 659-664.	2.5	39
142	Familial partial monosomy 7 and myelodysplasia. <i>Cancer Genetics and Cytogenetics</i> , 2001, 124, 147-151.	1.0	38
143	Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I. <i>Blood</i> , 2015, 125, 1662-1671.	1.4	37
144	Analysis of p53 gene mutations in acute myeloid leukemia. <i>American Journal of Hematology</i> , 1994, 46, 304-309.	4.1	36

#	ARTICLE	IF	CITATIONS
145	Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960–1999 and registered in the Italian Off-Therapy Registry. <i>European Journal of Cancer</i> , 2019, 110, 86-97.	2.8	36
146	Identification of new partner chromosomes involved in fusions with the ETV6 (TEL) gene in hematologic malignancies. <i>Genes Chromosomes and Cancer</i> , 1998, 21, 223-229.	2.8	35
147	Comparative analysis of multilineage properties of mesenchymal stromal cells derived from fetal sources shows an advantage of mesenchymal stromal cells isolated from cord blood in chondrogenic differentiation potential. <i>Cytotherapy</i> , 2014, 16, 893-905.	0.7	35
148	Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group. <i>Haematologica</i> , 2015, 100, e10-e13.	3.5	35
149	Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia. <i>Human Gene Therapy</i> , 2018, 29, 602-613.	2.7	35
150	Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. <i>Blood Transfusion</i> , 2010, 8, 63-5.	0.4	35
151	Characterization of the human myeloid leukemia-derived cell line GF-D8 by multiplex fluorescence in situ hybridization, subtelomeric probes, and comparative genomic hybridization. <i>Cancer</i> , 1999, 24, 213-221.		34
152	Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. <i>British Journal of Haematology</i> , 2002, 119, 445-453.	2.5	34
153	Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. <i>British Journal of Haematology</i> , 2015, 170, 398-407.	2.5	34
154	Emergency department use by paediatric patients in Lombardy Region, Italy: a population study. <i>BMJ Paediatrics Open</i> , 2018, 2, e000247.	1.4	34
155	Immunogenotype Changes Preval in Relapses of Young Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia and Derive Mainly from Clonal Selection. <i>Clinical Cancer Research</i> , 2005, 11, 7720-7727.	7.0	33
156	miRNA-regulated gene expression differs in celiac disease patients according to the age of presentation. <i>Genes and Nutrition</i> , 2015, 10, 482.	2.5	33
157	Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. <i>Haematologica</i> , 2020, 105, 1887-1894.	3.5	33
158	Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System. <i>Molecular Therapy</i> , 2020, 28, 1974-1986.	8.2	33
159	CD40 activation of BCP-ALL cells generates IL-10-producing, IL-12-defective APCs that induce allogeneic T-cell anergy. <i>Blood</i> , 2004, 104, 744-751.	1.4	32
160	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. <i>Haematologica</i> , 2019, 104, 1812-1821.	3.5	32
161	Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?. <i>Cells</i> , 2020, 9, 1337.	4.1	32
162	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , 2021, 8, e55-e66.	4.6	32

#	ARTICLE	IF	CITATIONS
163	Frequency of RAS and p53 Mutations in Acute Promyelocytic Leukemias. <i>Leukemia and Lymphoma</i> , 1993, 11, 405-410.	1.3	31
164	Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. <i>Haematologica</i> , 2007, 92, 381-388.	3.5	31
165	Development of an algorithm for the management of cervical lymphadenopathy in children: consensus of the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Society of Pediatric Infectious Diseases and the Italian Society of Pediatric Otorhinolaryngology. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1557-1567.	4.4	31
166	Heterogeneity of the 7q36 breakpoints in the t(7;12) involving ETV6 in infant leukemia. <i>Genes Chromosomes and Cancer</i> , 2003, 38, 191-200.	2.8	30
167	The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. <i>Cytotherapy</i> , 2009, 11, 403-413.	0.7	30
168	Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention. <i>Expert Review of Hematology</i> , 2015, 8, 57-70.	2.2	30
169	The presence of mutated and deleted <scp>PTEN</scp> is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with <scp>AIEOP</scp>â€<scp>BFM ALL</scp> protocols. <i>British Journal of Haematology</i> , 2018, 182, 705-711.	2.5	30
170	COVID-19 in Immunosuppressed Children. <i>Frontiers in Pediatrics</i> , 2021, 9, 629240.	1.9	30
171	Human cord blood CD34+ progenitor cells acquire functional cardiac properties through a cell fusion process. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H1875-H1884.	3.2	29
172	Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, e229-e232.	3.5	29
173	Molecular Diagnosis and Clinical Relevance of t(9;22), t(4;11) and t(1;19) Chromosome Abnormalities in a Consecutive Group of 141 Adult Patients with Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1996, 21, 457-466.	1.3	28
174	Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation. <i>Stem Cells International</i> , 2012, 2012, 1-6.	2.5	28
175	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. <i>Blood</i> , 2022, 139, 1785-1793.	1.4	28
176	PTX3 as a Potential Novel Tool for the Diagnosis and Monitoring of Pulmonary Fungal Infections in Immuno-compromised Pediatric Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 881-885.	0.6	27
177	Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis. <i>Biologicals</i> , 2013, 41, 439-445.	1.4	27
178	CD123 AML targeting by chimeric antigen receptors. <i>OncImmunology</i> , 2014, 3, e28835.	4.6	27
179	Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 327.	4.1	27
180	Collateral effects of COVID-19 pandemic in pediatric hematooncology: Fatalities caused by diagnostic delay. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28482.	1.5	26

#	ARTICLE	IF	CITATIONS
181	Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency. <i>Blood</i> , 2021, 137, 493-499.	1.4	26
182	Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. <i>Cancer</i> , 2017, 123, 3609-3616.	4.1	25
183	Surgical treatment of isolated tricuspid valve infective endocarditis: 25-year results from a multicenter registry. <i>International Journal of Cardiology</i> , 2019, 292, 62-67.	1.7	25
184	Pro-inflammatory cytokines favor the emergence of ETV6/RUNX1-positive pre-leukemic cells in a model of mesenchymal niche. <i>British Journal of Haematology</i> , 2020, 190, 262-273.	2.5	25
185	Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2021, 2, 835-852.	13.2	25
186	Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1996, 92, 653-658.	2.5	24
187	WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?. <i>European Journal of Haematology</i> , 2004, 73, 25-28.	2.2	24
188	Hurler Disease Bone Marrow Stromal Cells Exhibit Altered Ability to Support Osteoclast Formation. <i>Stem Cells and Development</i> , 2012, 21, 1466-1477.	2.1	24
189	Adolescents' Health Awareness and Understanding of Cancer and Tumor Prevention: When and Why an Adolescent Decides to Consult a Physician. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1357-1361.	1.5	24
190	Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. <i>Leukemia</i> , 2020, 34, 1694-1700.	7.2	24
191	BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy. <i>Haematologica</i> , 2020, 105, 2200-2204.	3.5	24
192	<i>CRLF2</i> over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 59260-59272.	1.8	24
193	An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. <i>Cancers</i> , 2021, 13, 6148.	3.7	24
194	IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis. <i>Laboratory Investigation</i> , 2009, 89, 1182-1186.	3.7	23
195	Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2011, 155, 45-52.	2.5	23
196	Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells. <i>British Journal of Haematology</i> , 1998, 103, 449-461.	2.5	22
197	Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. <i>Pediatric Blood and Cancer</i> , 2010, 54, 872-878.	1.5	22
198	Human umbilical cord blood-borne fibroblasts contain marrow niche precursors that form a bone/marrow organoid <i>in vivo</i> . <i>Development (Cambridge)</i> , 2017, 144, 1035-1044.	2.5	22

#	ARTICLE	IF	CITATIONS
199	<i>miR-155</i> : a new player in myeloid cell differentiation. <i>Haematologica</i> , 2019, 104, 1332-1341.	3.5	22
200	Maturation signatures of conventional dendritic cell subtypes in COVID-19 suggest direct viral sensing. <i>European Journal of Immunology</i> , 2022, 52, 109-122.	2.9	22
201	Location First: Targeting Acute Myeloid Leukemia Within Its Niche. <i>Journal of Clinical Medicine</i> , 2020, 9, 1513.	2.4	22
202	Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016). <i>Journal of Cancer Survivorship</i> , 2018, 12, 647-650.	2.9	21
203	ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. <i>Haematologica</i> , 2019, 104, 533-545.	3.5	21
204	Failure of interferon- $\gamma$ pre-treated mesenchymal stem cell treatment in a patient with Crohn's disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 4379.	3.3	21
205	Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. <i>Leukemia</i> , 2003, 17, 2247-2248.	7.2	20
206	Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors. <i>Immunology Letters</i> , 2013, 155, 43-46.	2.5	20
207	Childhood acute lymphoblastic leukemia in Nicaragua: Long-term results in the context of an international cooperative program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 827-832.	1.5	20
208	Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases. <i>British Journal of Haematology</i> , 2015, 169, 103-110.	2.5	20
209	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. <i>British Journal of Cancer</i> , 2017, 116, 335-343.	6.4	20
210	Modeling Cornelia de Lange syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation. <i>Human Molecular Genetics</i> , 2019, 28, 64-73.	2.9	20
211	Droplet Digital PCR Improves IG/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2021, 5, e543.	2.7	20
212	Molecular diagnosis and monitoring of acute myeloid leukemia. <i>Leukemia Research</i> , 1996, 20, 801-807.	0.8	19
213	In Vitro Comparison of Three Different Chimeric Receptor-modified Effector T-cell Populations for Leukemia Cell Therapy. <i>Journal of Immunotherapy</i> , 2011, 34, 469-479.	2.4	19
214	Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better?. <i>Journal of Inherited Metabolic Disease</i> , 2016, 39, 189-202.	3.6	19
215	Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies. <i>Human Gene Therapy</i> , 2017, 28, 231-241.	2.7	19
216	Engineered T cells towards TNFRSF13C ( <i>CD137</i> ): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 939-943.	2.5	19

#	ARTICLE	IF	CITATIONS
217	Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. <i>Haematologica</i> , 2019, 104, e13-e16.	3.5	19
218	Prevalence of Immunological Defects in a Cohort of 97 Rubinstein-Taybi Syndrome Patients. <i>Journal of Clinical Immunology</i> , 2020, 40, 851-860.	3.8	19
219	High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2017, 8, 42398-42413.	1.8	19
220	A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice. <i>Leukemia Research</i> , 1997, 21, 1107-1114.	0.8	18
221	A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood "high-risk" acute lymphoblastic leukaemia: a study of the AIEOP group. <i>British Journal of Haematology</i> , 2002, 118, 741-747.	2.5	18
222	Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1705-1716.	4.1	18
223	Acute myeloid leukaemia niche regulates response to L-asparaginase. <i>British Journal of Haematology</i> , 2019, 186, 420-430.	2.5	18
224	Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 273-286.	4.2	17
225	<i>lck</i> over-expression drives STAT5 oncogenic signaling in <i>PAX5</i> translocated BCP-ALL patients. <i>Oncotarget</i> , 2015, 6, 1569-1581.	1.8	17
226	Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities. <i>Haematologica</i> , 2016, 101, e95-e99.	3.5	17
227	Impact of COVID-19 on the Pattern of Access to a Pediatric Emergency Department in the Lombardy Region, Italy. <i>Pediatric Emergency Care</i> , 2020, 36, e597-e598.	0.9	17
228	Deletion of parental GST genes as a possible susceptibility factor in the etiology of infant leukemia. <i>Leukemia Research</i> , 2000, 24, 971-974.	0.8	16
229	Monitoring minimal residual disease using chromosomal translocations in childhood ALL. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 21-35.	1.7	16
230	GMPaC-based CD133 <sup>+</sup> cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 1619-1634.	3.6	16
231	Glutathione <i>S</i> -transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort. <i>Pharmacogenomics</i> , 2012, 13, 1905-1916.	1.3	16
232	Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia. <i>Leukemia Research</i> , 2013, 37, 928-935.	0.8	16
233	Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". <i>Haematologica</i> . 2013. 98. e164-e165.	3.5	16
234	Donor-derived CD19-targeted T cells in allogeneic transplants. <i>Current Opinion in Hematology</i> , 2015, 22, 497-502.	2.5	16

#	ARTICLE	IF	CITATIONS
235	CyclinD1 Down-Regulation and Increased Apoptosis Are Common Features of Cohesinopathies. <i>Journal of Cellular Physiology</i> , 2016, 231, 613-622.	4.1	16
236	A (15;17) translocation not associated with acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 1996, 95, 706-709.	2.5	15
237	Monitoring of minimal residual disease in leukemia, advantages and pitfalls. <i>Annals of Medicine</i> , 2006, 38, 512-521.	3.8	15
238	Spiritual Support for Adolescent Cancer Patients: A Survey of Pediatric Oncology Centers in Italy and Spain. <i>Tumori</i> , 2016, 102, 376-380.	1.1	15
239	Ataluren-driven restoration of Shwachman-Bodian-Diamond syndrome protein function in Shwachman-Diamond syndrome bone marrow cells. <i>American Journal of Hematology</i> , 2018, 93, 527-536.	4.1	15
240	PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 415-425.	2.0	15
241	The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPI) Tj ETQq1 1 0.784314 rgBT /Overlock 15	3.8	15
242	Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 1157-1171.	2.5	15
243	Establishment of human acute myelogenous leukemia lines secreting interleukin-1 $\beta$ in SCID mice. <i>International Journal of Cancer</i> , 1995, 61, 280-285.	5.1	14
244	Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002, 118, 1011-1018.	2.5	14
245	Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. <i>Transfusion</i> , 2005, 45, 1214-1220.	1.6	14
246	Reconstitution of lymphocyte subpopulations in children with inherited metabolic storage diseases after haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2005, 130, 249-255.	2.5	14
247	Abnormally expanded pro-B hematogones associated with congenital cytomegalovirus infection. <i>American Journal of Hematology</i> , 2007, 82, 934-936.	4.1	14
248	Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 563-566.	2.3	14
249	Partial duplication of the <i>PARK2</i> gene in a child with developmental delay and her normal mother: A second report. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 485-486.	1.7	14
250	Adolescents with Cancer in Italy: Improving Access to National Cooperative Pediatric Oncology Group (AIEOP) Centers. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1116-1119.	1.5	14
251	Paediatric non-Hodgkin lymphoma in low and middle income countries. <i>British Journal of Haematology</i> , 2016, 173, 651-654.	2.5	14
252	Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia. <i>Journal of Autoimmunity</i> , 2017, 85, 141-152.	6.5	14

#	ARTICLE	IF	CITATIONS
253	Human aplastic anaemia-derived mesenchymal stromal cells form functional haematopoietic stem cell niche <i>in vivo</i> . <i>British Journal of Haematology</i> , 2017, 179, 669-673.	2.5	14
254	Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. <i>European Journal of Cancer</i> , 2019, 122, 61-71.	2.8	14
255	Results of a multicenter universal newborn screening program for sickle cell disease in Italy: A call to action. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27657.	1.5	14
256	Intermittent granulocyte maturation arrest, hypocellular bone marrow, and episodic normal neutrophil count can be associated with SRP54 mutations causing Shwachman-Diamond-like syndrome. <i>British Journal of Haematology</i> , 2020, 189, e171-e174.	2.5	14
257	Acute myeloid leukemia shapes the bone marrow stromal niche <i>in vivo</i> . <i>Haematologica</i> , 2021, 106, 865-870.	3.5	14
258	Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 618164.	3.7	14
259	ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment. <i>Blood Advances</i> , 2021, 5, 5164-5178.	5.2	14
260	Reciprocal translocation t(12;13)(p13;q14) in acute nonlymphoblastic leukemia: Report and cytogenetic analysis of two cases. <i>Cancer Genetics and Cytogenetics</i> , 1994, 77, 106-110.	1.0	13
261	Immunoglobulin Light Chain Kappa Deletion Rearrangement as a Marker of Clonality in Mantle Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 1999, 36, 147-150.	1.3	13
262	Two cases of hepatic adenomas in patients with wolff-hirschhorn syndrome: A new rare complication?. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 1759-1762.	1.2	13
263	Mesenchymal stromal cells from Shwachman-Diamond syndrome patients fail to recreate a bone marrow niche <i>in vivo</i> and exhibit impaired angiogenesis. <i>British Journal of Haematology</i> , 2018, 182, 114-124.	2.5	13
264	A Simple RNA Target Capture NGS Strategy for Fusion Genes Assessment in the Diagnostics of Pediatric B-cell Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2019, 3, e250.	2.7	13
265	Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K / Akt and JAK-STAT signaling pathways. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 491-503.	1.5	13
266	Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. <i>Leukemia</i> , 2020, 34, 3042-3046.	7.2	13
267	Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia. <i>Stem Cells</i> , 1994, 12, 394-401.	3.2	12
268	Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2003, 17, 981-983.	7.2	12
269	CD34+ Stem Cell Recovery After Positive Selection of "Overloaded" Immunomagnetic Columns. <i>Stem Cells and Development</i> , 2005, 14, 740-743.	2.1	12
270	A new case report of severe mucopolysaccharidosis type VII: diagnosis, treatment with haematopoietic cell transplantation and prenatal diagnosis in a second pregnancy. <i>Italian Journal of Pediatrics</i> , 2018, 44, 128.	2.6	12



#	ARTICLE	IF	CITATIONS
271	Recurrent genetic fusions redefine <i>MLL</i> germ line acute lymphoblastic leukemia in infants. <i>Blood</i> , 2021, 137, 1980-1984.	1.4	12
272	Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e507-e516.	3.9	12
273	Identification of Two Novel Isoforms of the ZNF162 Gene: A Growing Family of Signal Transduction and Activator of RNA Proteins. <i>Genomics</i> , 1997, 42, 268-277.	2.9	11
274	Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T cell lines by means of an automated elutriation device. <i>Transfusion</i> , 2008, 48, 1644-1649.	1.6	11
275	Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, e14-e17.	3.5	11
276	Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27431.	1.5	11
277	Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. , 2021, 9, e002026.		11
278	Childhood cancer in Italy: background, goals, and achievements of the Italian Paediatric Hematology Oncology Association (AIEOP). <i>Tumori</i> , 2021, 107, 370-375.	1.1	11
279	Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials. <i>Blood</i> , 1997, 90, 571-577.	1.4	11
280	SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2018, 9, 22872-22885.	1.8	11
281	Clinical Relevance of the PML/RAR- $\alpha$ Gene Rearrangement in Acute Promyelocytic Leukaemia. <i>Leukemia and Lymphoma</i> , 1994, 12, 327-332.	1.3	10
282	Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status. <i>British Journal of Haematology</i> , 1997, 96, 308-313.	2.5	10
283	Case of congenital hypotransferrinemia suggests that tissue hypoxia during fetal development may cause hypospadias. <i>American Journal of Medical Genetics Part A</i> , 2000, 95, 287-287.	2.4	10
284	Association of gastric and Waldeyer's ring lymphoma: a molecular study. , 2000, 18, 15-19.		10
285	Promoter Analysis of TFPT (FB1), a Molecular Partner of TCF3 (E2A) in Childhood Acute Lymphoblastic Leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2001, 288, 1250-1257.	2.1	10
286	Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 623-638.	1.7	10
287	Stem cells in severe infantile spinal muscular atrophy (SMA1). <i>Neuromuscular Disorders</i> , 2012, 22, 1032-1034.	0.6	10
288	Cytoskeletal Regulatory Gene Expression and Migratory Properties of B-cell Progenitors Are Affected by the ETV6-RUNX1 Rearrangement. <i>Molecular Cancer Research</i> , 2014, 12, 1796-1806.	3.4	10

#	ARTICLE	IF	CITATIONS
289	A European paediatric cancer mission: aspiration or reality?. <i>Lancet Oncology</i> , The, 2019, 20, 1200-1202.	10.7	10
290	First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia. <i>Journal of Clinical Pathology</i> , 2019, 72, 558-561.	2.0	10
291	Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model. <i>Molecular Genetics and Metabolism</i> , 2020, 130, 197-208.	1.1	10
292	Double target in situ hybridization applied to the study of numerical aberrations in childhood acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1994, 73, 103-108.	1.0	9
293	Successful Application of OPLS-DA for the Discrimination of Wild-Type and Mutated Cells in Acute Lymphoblastic Leukemia. <i>QSAR and Combinatorial Science</i> , 2009, 28, 822-828.	1.4	9
294	Williams syndrome and mature B-Leukemia: A random association?. <i>European Journal of Medical Genetics</i> , 2016, 59, 634-640.	1.3	9
295	Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I. <i>Scientific Reports</i> , 2017, 7, 9473.	3.3	9
296	Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia. <i>Experimental Hematology</i> , 2019, 73, 7-12.e4.	0.4	9
297	Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study. <i>European Journal of Cancer</i> , 2020, 137, 224-234.	2.8	9
298	Potential use of CD40 ligand for immunotherapy of childhood B-cell precursor acute lymphoblastic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 465-477.	1.7	8
299	Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2010, 85, 138-141.	4.1	8
300	New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future. <i>Italian Journal of Pediatrics</i> , 2011, 37, 46.	2.6	8
301	The Effects of Propofol and Ketamine on the Cytokine Levels of Children With Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, e296-e300.	0.6	8
302	“There's no Reason why”: A Campaign to Raise Cancer Awareness among Adolescents. <i>Tumori</i> , 2016, 102, 270-275.	1.1	8
303	<sc>TNFRSF</sc>13C (<sc>BAFFR</sc>) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 434-436.	2.5	8
304	Dysregulation of NIPBL leads to impaired RUNX1 expression and haematopoietic defects. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6272-6282.	3.6	8
305	Primary immunodeficiencies, autoimmune hyperthyroidism, coeliac disease and systemic lupus erythematosus in childhood immune thrombocytopenia. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 643-651.	1.5	8
306	PCR Technology to Identify Minimal Residual Disease. <i>Methods in Molecular Biology</i> , 2021, 2185, 77-94.	0.9	8

#	ARTICLE	IF	CITATIONS
307	Lessons After the Early Management of the COVID-19 Outbreak in a Pediatric Transplant and Hemato-Oncology Center Embedded within a COVID-19 Dedicated Hospital in Lombardia, Italy. &lt;i&gt;Estote Parati.&lt;/i&gt; (Be Ready). SSRN Electronic Journal, 0, , .	0.4	8
308	Intercontinental collaboration in clinical trials for children and adolescents with cancerâ€™A systematic review by ACCELERATE. Cancer Medicine, 2021, 10, 8462-8474.	2.8	8
309	Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after lowâ€™risk relapse. Pediatric Blood and Cancer, 2011, 57, 654-659.	1.5	7
310	An Attempt to Induce Transient Immunosuppression Pre-Erythrocytapheresis in a Girl with Sickle Cell Disease, a History of Severe Delayed Hemolytic Transfusion Reactions and Need for Hip Prosthesis. Hematology Reports, 2013, 5, e11.	0.8	7
311	Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories. Cytotherapy, 2016, 18, 481-486.	0.7	7
312	Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. Blood, 2017, 130, 2146-2149.	1.4	7
313	Fusion of ETV6 to the Caudal-Related Homeobox Gene CDX2 in Acute Myeloid Leukemia With the t(12;13)(p13;q12). Blood, 1999, 93, 1025-1031.	1.4	7
314	The Tyrosine Kinase Abl-Related Gene ARG Is Fused toETV6 in an AML-M4Eo Patient With a t(1;12)(q25;p13): Molecular Cloning of Both Reciprocal Transcripts. Blood, 1999, 94, 4370-4373.	1.4	7
315	Expression and modulation of a mononuclear phagocyte differentiation antigen (PAM-1) during in vitro maturation of peripheral blood monocytes. International Journal of Clinical and Laboratory Research, 1993, 23, 83-87.	1.0	6
316	ETV6â€™RUNX1 fusion gene and additional genetic changes in infant leukemia: a genome-wide analysis. Cancer Genetics and Cytogenetics, 2009, 193, 86-92.	1.0	6
317	Gain-of-function mutations in interleukin-7 receptor-1± (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 1333-1333.	8.5	6
318	Loss of <sc>CBL</sc> E3â€™ligase activity in Bâ€™lineage childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2012, 159, 115-119.	2.5	6
319	Aorta to right atrial shunt due to the rupture of a degenerative aneurysm of the noncoronary sinus of Valsalva. Journal of Cardiovascular Medicine, 2013, 14, 71-73.	1.5	6
320	Cervical spine malformation in cornelia de lange syndrome: A report of three patients. American Journal of Medical Genetics, Part A, 2014, 164, 1520-1524.	1.2	6
321	Hepatic Granulomatous Lesions Caused by Systemic Bartonella vinsonii subsp. arupensis Infection in a Child. Pediatric Infectious Disease Journal, 2015, 34, 1416-1417.	2.0	6
322	Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133<sup><b>+</b></sup> Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy. BioMed Research International, 2015, 2015, 1-10.	1.9	6
323	Mesenchymal stromal cellâ€™secreted chemerin is a novel immunomodulatory molecule driving the migration of ChemR23-expressing cells. Cytotherapy, 2017, 19, 200-210.	0.7	6
324	The new frame for Mucopolysaccharidoses. Italian Journal of Pediatrics, 2018, 44, 117.	2.6	6

#	ARTICLE	IF	CITATIONS
325	Evaluation of the Pattern of Use of a Pediatric Emergency Department in Italy. <i>Pediatric Emergency Care</i> , 2021, 37, e1494-e1498.	0.9	6
326	Commitment of juvenile myelo-monocytic (JMML) leukemic cells to spontaneously differentiate into dendritic cells. <i>The Hematology Journal</i> , 2002, 3, 302-310.	1.4	6
327	Inhibition of Granulocyte-Macrophage Colony-Stimulating Factor Prevents Dissemination and Induces Remission of Juvenile Myelomonocytic Leukemia in Engrafted Immunodeficient Mice. <i>Blood</i> , 1997, 90, 4910-4917.	1.4	6
328	Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation. <i>Oncotarget</i> , 2016, 7, 82123-82138.	1.8	6
329	Precursor B-cell acute lymphoblastic leukaemia—a global view. <i>British Journal of Haematology</i> , 2022, 196, 530-547.	2.5	6
330	Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 1996, 89, 153-156.	1.0	5
331	Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library. <i>Experimental Hematology</i> , 2008, 36, 473-485.	0.4	5
332	From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders. <i>Current Pharmaceutical Design</i> , 2012, 18, 5776-5781.	1.9	5
333	Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 612-619.	2.5	5
334	Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives. <i>Frontiers in Oncology</i> , 2013, 3, 106.	2.8	5
335	A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in <i>RAF1</i> . <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 1401-1404.	1.2	5
336	Hodgkin lymphoma in a patient with mosaic trisomy 18: First clinical observation. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 777-780.	1.2	5
337	From Adjustment to Thriving: Exploring Well-Being in Young Adult Survivors of Childhood Cancer and Their Siblings. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 330-336.	1.3	5
338	Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1267-1271.	2.3	5
339	Impairment of Retinoic Acid Signaling in Cornelia de Lange Syndrome Fibroblasts. <i>Birth Defects Research</i> , 2017, 109, 1268-1276.	1.5	5
340	Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience. <i>Acta Haematologica</i> , 2018, 140, 105-111.	1.4	5
341	Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, e101-e105.	2.5	5
342	Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis. <i>Frontiers in Immunology</i> , 2021, 12, 673487.	4.8	5

#	ARTICLE	IF	CITATIONS
343	Serum anti-M $\beta$ 2-microglobulin as a marker of ovarian reserve after cancer treatment and/or hematopoietic stem cell transplantation in childhood: proposal for a systematic approach to gonadal assessment. <i>European Journal of Endocrinology</i> , 2021, 185, 717-728.	3.7	5
344	TEL/ARG induces cytoskeletal abnormalities in 293T cells. <i>Cancer Letters</i> , 2006, 241, 79-86.	7.2	4
345	Tailoring treatment strategy for acute promyelocytic leukemia in low-income countries. <i>Pediatric Blood and Cancer</i> , 2009, 53, 303-305.	1.5	4
346	Genomic Imbalances Are Confined to Non-Proliferating Cells in Paediatric Patients with Acute Myeloid Leukaemia and a Normal or Incomplete Karyotype. <i>PLoS ONE</i> , 2011, 6, e20607.	2.5	4
347	Thrombocytopenia and Cornelia de Lange syndrome: Still an enigma?. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 130-134.	1.2	4
348	Rings and Bricks: Expression of Cohesin Components is Dynamic during Development and Adult Life. <i>International Journal of Molecular Sciences</i> , 2018, 19, 438.	4.1	4
349	A novel <i>EP300</i> mutation associated with Rubinstein-Taybi syndrome type 2 presenting as combined immunodeficiency. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 776-781.	2.6	4
350	Evaluation of Technical Issues in a Pilot Multicenter Newborn Screening Program for Sickle Cell Disease. <i>International Journal of Neonatal Screening</i> , 2019, 5, 2.	3.2	4
351	More than an "atypical" phenotype: dual molecular diagnosis of autoimmune lymphoproliferative syndrome and Becker muscular dystrophy. <i>British Journal of Haematology</i> , 2020, 191, 291-294.	2.5	4
352	Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis. <i>Annals of Hematology</i> , 2021, 100, 105-116.	1.8	4
353	Acute Rheumatic Fever: Where Do We Stand? An Epidemiological Study in Northern Italy. <i>Frontiers in Medicine</i> , 2021, 8, 621668.	2.6	4
354	A new report of Cornelia de Lange syndrome associated with split hand and feet. <i>American Journal of Medical Genetics, Part A</i> , 2012, 158A, 2953-2955.	1.2	3
355	Neutropenia, hypogammaglobulinemia, and pneumonia: A case of WHIM syndrome. <i>Pediatrics International</i> , 2018, 60, 318-319.	0.5	3
356	Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib. <i>British Journal of Haematology</i> , 2018, 180, 895-898.	2.5	3
357	High <i>EVI1</i> Expression due to <i>NRIP1/EVI1</i> Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case. <i>HemaSphere</i> , 2020, 4, e471.	2.7	3
358	Growth patterns in children with mucopolysaccharidosis type I-Hurler after hematopoietic stem cell transplantation: Comparison with untreated patients. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 28, 100787.	1.1	3
359	The Impact of a Precision-Based Exercise Intervention in Childhood Hematological Malignancies Evaluated by an Adapted Yo-Yo Intermittent Recovery Test. <i>Cancers</i> , 2022, 14, 1187.	3.7	3
360	Germline mosaicism in cornelia de lange syndrome: Dilemmas and risk figures. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 1825-1826.	1.2	2

#	ARTICLE	IF	CITATIONS
361	Heterozygous Mutation in Adenosine Deaminase Gene in a Patient With Severe Lymphopenia Following Corticosteroid Treatment of Autoimmune Hemolytic Anemia. <i>Frontiers in Pediatrics</i> , 2018, 6, 272.	1.9	2
362	Globalization of pediatric research: pharmacological RCTs in Latin America. <i>Italian Journal of Pediatrics</i> , 2019, 45, 29.	2.6	2
363	Dexamethasone Stimulation Test in the Diagnostic Work-Up of Growth Hormone Deficiency in Childhood: Clinical Value and Comparison With Insulin-Induced Hypoglycemia. <i>Frontiers in Endocrinology</i> , 2020, 11, 599302.	3.5	2
364	Germline TP53 Mutation in an Adolescent With CMML/Atypical CML and Familial Cancer Predisposition. <i>HemaSphere</i> , 2020, 4, e460.	2.7	2
365	Spirometry monitoring in asthmatic children in Lombardy Region, Italy. <i>BMJ Paediatrics Open</i> , 2018, 2, e000334.	1.4	1
366	La Pediatria davanti alla sfida della Medicina di precisione. <i>Medico E Bambino</i> , 2021, 40, 7-8.	0.1	1
367	Evidence of treatment benefits in patients with MPSI-Hurler in long-term follow up using a new MRI scoring system. <i>Journal of Pediatrics</i> , 2021, , .	1.8	1
368	Acute Lymphoblastic Leukemia. , 2007, , 337-347.		1
369	Minimal residual disease. , 2006, , 679-706.		1
370	Expression of Myeloid Markers Lacks Prognostic Impact in Children Treated for Acute Lymphoblastic Leukemia: Italian Experience in AIEOP-ALL 88-91 Studies. <i>Blood</i> , 1998, 92, 795-801.	1.4	1
371	Cytokine release syndrome after CAR infusion in pediatric patients with refractory/relapsed B-ALL: is there a role for diclofenac?. <i>Tumori</i> , 2021, , 030089162110533.	1.1	1
372	Osteopathic Treatment and Evaluation in the Clinical Setting of Childhood Hematological Malignancies. <i>Cancers</i> , 2021, 13, 6321.	3.7	1
373	Identification of chromosomal rearrangements in the human myeloid leukemia cell line GF-D8 by dual-colour fluorescence in situ hybridization. <i>Hematological Oncology</i> , 1995, 13, 177-183.	1.7	0
374	A case of Philadelphia Positive Acute Lymphoblastic Leukaemia with three different phenotypic lineage, each one presenting the same BCR-ABL hybrid transcript. <i>Leukemia Research</i> , 2009, 33, e175-e177.	0.8	0
375	Minimal residual disease. , 0, , 632-659.		0
376	The authors reply. <i>Critical Care Medicine</i> , 2014, 42, e729-e730.	0.9	0
377	The authors reply. <i>Critical Care Medicine</i> , 2014, 42, e247-e248.	0.9	0
378	Acute Promyelocytic Leukaemia. , 2010, , 83-108.		0

#	ARTICLE	IF	CITATIONS
379	Acute Lymphoblastic Leukemia. , 2016, , 561-577.		0
380	A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia: A Single-Arm, Intergroup Study (Esphall 2010). SSRN Electronic Journal, 0, , .	0.4	0
381	A primarily clinician's responsibility. Pediatric Blood and Cancer, 2022, 69, e29612.	1.5	0
382	Similar outcome of tricuspid valve repair and replacement for isolated tricuspid infective endocarditis. Journal of Cardiovascular Medicine, 2022, 23, 406-413.	1.5	0